AZ-PRMT5i-1 (Compound 28) is an effective, orally-active MTAP-selective PRMT5 inhibitor. It exhibits synergistic properties with MTA and demonstrates anti-tumor activity both in vivo and in vitro, making it suitable for research in cancers lacking MTAP.
Target:
Histone Methyltransferase
* VAT and and shipping costs not included. Errors and price changes excepted
